araag2/HINT huggingface dataset:
Clinical trial NCT01224860 (phase 2, status: completed)
Conditions: renal transplant
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: telmisartan, losartan
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent;

          -  Age > 18 years;

          -  Single renal transplant or dual marginal > 6 months duration;

          -  Blood pressure >130/85 mmHg or need for anti-hypertensive therapy;

          -  Stable renal function (changes in serum creatinine < 30%) and no acute rejection
             episodes in the last six months;

          -  Stable (for at least six months) dual or triple immunosuppressive therapy including
             corticosteroids or calcineurin inhibitors;

          -  Legal capacity.

        Exclusion Criteria:

          -  Vascular disease of the kidney;

          -  Heart failure: NYHA classification class III-IV on ACE or AII inhibitor therapy;

          -  Cerebral haemorrhage, stroke or TIA within three months prior to study enrolment;

          -  Myocardial infarction within three months prior to study enrolment;

          -  Unstable angina pectoris;

          -  Severe hepatic disease;

          -  Pregnancy or women of child-bearing potential without following a scientifically
             accepted form of contraception;

          -  Overt diabetes or concomitant treatment with oral antidiabetic agents and/or insulin;

          -  Specific clinical indication (other than arterial hypertension) to be treated with ACE
             inhibitors or AII receptor antagonists;

          -  Specific contraindications or history of hypersensitivity to the study drugs,
             glitazones, ACE inhibitors or AII receptor antagonists;

          -  Participation to other clinical trials over the last three months;

          -  Legal incapacity;

          -  Previous diagnosis of: intellectual disability/mental retardation, dementia,
             schizophrenia.
Clinical trial NCT00420342 (phase 2, status: completed)
Conditions: postmenopause, hypertension, pre-hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10, O11.1, O11.2, O11.3, O11.4, O11.9, O11.5, O10.02
Drugs: drospirenone/17ß-estradiol (angeliq, bay86-4891), drospirenone/17ß-estradiol (angeliq, bay86-4891), sh k 00641 c - medroxyprogesterone acetate / conjugated equine (prempro tm)
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

        - Postmenopausal women 45 - 65 years old with prehypertension

        Exclusion Criteria:

        - Hormone therapy (estrogen/progestin)
Clinical trial NCT00396201 (phase 2, status: completed)
Conditions: hodgkin's disease
ICD codes: C81.77, C81.97, C81.17, C81.27, C81.37, C81.47, C81.70
Drugs: g-csf plus plerixafor
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of HD eligible for autologous transplantation

          -  No more than 3 prior regimens of chemotherapy (Rituximab is not considered
             chemotherapy for the purpose of this study.)

          -  4 weeks since last cycle of chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  The patient has recovered from all acute toxic effects of prior chemotherapy

          -  White blood cell count (WBC) >3.0*10^9/L

          -  Absolute polymorphonuclear cells (PMN) count >1.5*10^9/L

          -  Platelet (PLT) count >100*10^9/L

          -  Serum creatinine ≤2.2 mg/DL

          -  Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase
             (SGPT) and total bilirubin <2 x upper limit of normal (ULN)

          -  Left ventricle ejection fraction >45% by normal echocardiogram or multiple-gated
             acquisition (MUGA) scan

          -  Forced expiratory volume of the lung in the first second (FEV1) >60% of predicted or
             diffusing capacity of the lung for carbon monoxide (DLCO) >45% of predicted

          -  Negative for human immunodeficiency virus (HIV)

        Exclusion Criteria:

          -  A co-morbid condition which, in the view of the investigator, renders the patient at
             high risk for treatment complications

          -  Patients who have failed previous collections

          -  A residual acute medical condition resulting from prior chemotherapy

          -  Hodgkin's disease involving the central nervous system

          -  Acute infection

          -  Fever (temp >38°C/100.4°F)

          -  Patients whose actual body weight exceeds 150% of their ideal body weight

          -  History of ventricular arrhythmias

          -  History of paresthesias

          -  Patients who previously received experimental therapy within 4 weeks of enrolling in
             this study or who are currently enrolled in another experimental study during the
             mobilization period
Clinical trial NCT00098371 (phase 2, status: terminated)
Conditions: b-cell chronic lymphocytic leukemia, prolymphocytic leukemia, refractory chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10, C91.31, C91.32, C91.61, C91.62, C91.30, C91.60, A87.2, K52.832, D72.111, C91.11, C91.12, C91.10
Drugs: alvocidib
SMILES: CN1CC[C@@H]([C@H](O)C1)C1=C(O)C=C(O)C2=C1OC(=CC2=O)C1=CC=CC=C1Cl
Reason stopped: 
    ctep initiated action.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed B-cell chronic lymphocytic leukemia (CLL) or prolymphocytic
             leukemia (PLL) arising from CLL

               -  No de novo PLL

               -  Lymphocyte count > 5,000/mm^3 at some point since initial diagnosis of CLL

               -  B-cells co-expressing CD5 AND CD19 or CD20

               -  If no dim serum immunoglobulin or CD23 expression on leukemia cells, must be
                  examined for cyclin D1 overexpression OR t(11;14) to rule out mantle cell
                  lymphoma

          -  Requiring therapy, defined by any of the following:

               -  Massive or progressive splenomegaly and/or lymphadenopathy

               -  Anemia (hemoglobin < 11 g/dL) OR thrombocytopenia (platelet count < 100,000/mm^3)

               -  Weight loss > 10% within the past 6 months

               -  Grade 2 or 3 fatigue

               -  Fevers > 100.5°C or night sweats for > 2 weeks with no evidence of infection

               -  Progressive lymphocytosis with an increase of > 50% over a 2-month period OR an
                  anticipated doubling time < 6 months

          -  Received ≥ 1 prior chemotherapy regimen that included fludarabine or nucleoside
             equivalent OR alternative therapy if contraindication to fludarabine exists (i.e.,
             autoimmune hemolytic anemia)

          -  Performance status - ECOG 0-2

          -  More than 2 years

          -  See Disease Characteristics

          -  Baseline cytopenias allowed

          -  WBC ≤ 200,000/mm^3

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless due to Gilbert's disease,
             hemolysis, or disease infiltration of the liver)

          -  AST ≤ 2 times ULN (unless due to hemolysis or disease infiltration of the liver)

          -  Creatinine ≤ 2.0 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other malignancy that would limit life expectancy

          -  See Disease Characteristics

          -  No other concurrent chemotherapy

          -  No concurrent chronic corticosteroids or corticosteroids as antiemetics

          -  No concurrent hormonal therapy except steroids for new adrenal failure or hormones for
             nondisease-related conditions (e.g., insulin for diabetes)

          -  No concurrent radiotherapy
Clinical trial NCT00385099 (phase 2, status: completed)
Conditions: irritable colon
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: gw876008
SMILES: CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
Eligibility criteria:

        Inclusion criteria:

          -  Must have irritable bowel syndrome.

        Exclusion criteria:

          -  Subjects who have been taking any medication for the treatment of irritable bowel
             syndrome within 6 months prior to the start of the study.
Clinical trial NCT00706953 (phase 2, status: withdrawn)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib; pegylated liposomal doxorubicin
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of Multiple Myeloma

          -  Received prior courses of bortezomib (VELCADE)-based therapy

          -  Greater than or equal to 50% reduction in M-Protein sustained for a minimum of 60 days
             and no evidence of progression of disease while on the most recent course of
             VELCADE-based therapy

          -  60 days or more since the patient's last VELCADE dose

          -  Life expectancy > 3 months

          -  Progressive disease defined by new or worsening lytic bone lesions or plasmacytoma or
             hypercalcemia or a >25% increase in M-protein

        Exclusion Criteria:

          -  No patients with progressive disease while receiving an anthracycline-based regimen

          -  No patients with >2 prior regimens for the treatment of multiple myeloma

          -  No major surgery within 2 weeks before screening

          -  No patients with history of allergic reaction to compounds containing boron, mannitol,
             anthracycline, or liposomal formulations of any agent

          -  No patients known to be human immunodeficiency virus (HIV) positive

          -  No patients with poorly controlled hypertension, diabetes mellitus, or other serious
             medical or psychiatric illness

          -  No patients with an active systemic infection requiring treatment
Clinical trial NCT01554579 (phase 2, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: gefapixant, sugar pill
SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women

          -  Women of child bearing potential must not be pregnant during the study and must use
             two forms of birth control

          -  Men and their female partners must use two forms of birth control

          -  Clinical and radiographic evidence of chronic knee osteoarthritis

          -  An average NPRS score of >=5 and <=9 over a 4-7 day washout period of their previous
             osteoarthritis medications

          -  Ambulatory

          -  Have provided written informed consent
Clinical trial NCT00307164 (phase 2/phase 3, status: completed)
Conditions: hiv infections, lipoatrophy
ICD codes: Z21
Drugs: nucleomaxx, nucleomaxx placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-1 infected

          -  Stable ART containing zidovudine or stavudine for at least 12 consecutive weeks prior
             to study entry

          -  Cumulative ART with zidovudine or stavudine for at least 24 weeks prior to study entry

          -  Viral load of 5,000 copies/ml or less within 45 days prior to study entry

          -  Lipoatrophy in at least two of the following areas: face, arms, legs, OR buttocks

          -  Not planning to add to or change current vitamin supplementation

          -  Willing to use acceptable forms of contraception

        Exclusion Criteria:

          -  Life expectancy of less than 12 months

          -  Currently enrolled in or planning to enroll in an ART interruption study

          -  Plans to change current ART regimen

          -  Liver failure at anytime prior to study entry

          -  Greater than Grade 2 diarrhea or vomiting within 7 days prior to study entry

          -  Current AIDS-defining opportunistic infection or illness. Individuals with cutaneous
             Kaposi's sarcoma not requiring chemotherapy are not excluded.

          -  Currently receiving insulin or oral hypoglycemic products for diabetes mellitus

          -  Systemic cancer chemotherapy or immunomodulating agents within 30 days prior to study
             entry

          -  Systemic steroids for a cumulative duration of longer than 4 weeks within the 6 months
             prior to study entry

          -  Known allergy or sensitivity to study drug or any of its components

          -  Severe lactose intolerance

          -  Current drug or alcohol abuse or dependence

          -  Clinically significant illness requiring systemic treatment or hospitalization

          -  Chronic disability or serious illness that may affect body composition

          -  Received an investigational drug other than NucleomaxX or uridine for lipoatrophy
             within 30 days prior to study entry

          -  Certain abnormal laboratory values

          -  Pregnancy or breastfeeding
Clinical trial NCT00169221 (phase 2, status: terminated)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: iressa (gefitinib)
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Reason stopped: 
    toxicity in an independent study imex. the trial was subsequently terminated (54 pts instead of
    140) despite safety analyses showing no excess of toxicity
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with upper aerodigestive tract carcinomas (all sites included) having
             surgical resection and eligible for post-operative radiation + cisplatin.

          -  Patient having a tumoral biopsy (0.5 - 1 cm3) stored in liquid nitrogen at time of
             surgical resection (patients with small tumors located in larynx for instance will not
             be included)

          -  Patients receiving post-operative radiation (>=60 Gy on tumor bed and/or cervical
             area), associated with cisplatin, 6 weeks after surgery at the latest.

        Exclusion Criteria:

          -  previous history of cancer (except skin basal cell carcinoma)
Clinical trial NCT00073034 (phase 2, status: terminated)
Conditions: diabetes mellitus, diabetic neuropathy, painful
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9, G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3
Drugs: eaa-090
SMILES: OP(O)(=O)CCN1CCCNC2=C1C(=O)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women of childbearing potential must have a negative serum pregnancy test result at
             screening

          -  Diabetes mellitus (type I or II) that is controlled by oral or parenteral hypoglycemic
             agents or diet

          -  Diagnosis of painful diabetic distal symmetric sensory/motor polyneuropathy

        Exclusion Criteria:

          -  Pregnancy, lactation, or plans to become pregnant during the study

          -  Depo-Provera or oral contraceptives that have been taken for less than 1 month before
             study day 1 if not using another medically accepted form of birth control

          -  History of multiple drug allergies that may put the subject at greater risk during
             study participation in the opinion of the investigator
Clinical trial NCT01472939 (phase 2, status: completed)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: ssp-002358 (0.1 mg) + ppi, ssp-002358 (0.5 mg) + ppi, ssp-002358 (2.0 mg) + ppi, placebo + ppi
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Written Informed Consent Form signed voluntarily before the first study-related
             activity.

          2. Aged between 18 and 70 years, inclusive.

          3. Subjects with a history of the cardinal symptoms of GERD (both heartburn and
             regurgitation) prior to PPI therapy.

          4. Subjects with symptoms of GERD for at least 6 months prior to the Screening Visit.

          5. Subjects who have persistent symptoms of regurgitation for 3 or more days over the
             past week with or without heartburn while on PPI.

          6. Subjects have at least some improvement to the symptom of heartburn while on PPI
             therapy.

          7. Subjects on PPI therapy for at least 8 weeks prior to the Screening Visit of which the
             last 4 weeks are on a stable labeled dose for any GERD indication according to the
             country label, where a change of PPI therapy would not impact the symptoms
             (twice-daily dosing of PPI is not allowed in the last 4 weeks)

        Exclusion Criteria:

          1. Subjects who show no response to heartburn while on PPI therapy.

          2. Subjects with dyspepsia symptoms that are more predominant than their GERD symptoms
             (heartburn and/or regurgitation).

          3. Subjects with prior endoscopic anti-reflux procedure or major GI surgery or subjects
             with major GI disorders.

          4. Presence of severe and clinically uncontrolled cardiovascular, liver, lung or
             neurologic disease, cancer or AIDS.

          5. Alarm symptoms suggestive of malignancies or organic disease.
Clinical trial NCT01505881 (phase 2, status: terminated)
Conditions: thromboembolism, heart valve prosthesis
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: dabigatran etexilate low dose, warfarin 5mg, dabigatran etexilate intermediate dose, warfarin 1mg, dabigatran etexilate high dose, warfarin 3mg
SMILES: CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Eligibility criteria:

        Inclusion criteria:

          1. Completed study 1160.113 per protocol

          2. Continuing need for anticoagulation

        Exclusion criteria:

          1. uncontrolled hypertension

          2. severe renal impairment

          3. active liver disease

          4. increased risk of bleeding
Clinical trial NCT02898012 (phase 2, status: completed)
Conditions: glioblastoma multiforme, primary brain tumor
ICD codes: L51.0, L51.8, L51.9
Drugs: temozolomide, bevacizumab
SMILES: CSCC[C@H](N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Supratentorial Glioblastoma diagnosed by biopsy.

          -  Patients aged ≥ 70 years

          -  KPS >30 and < 70

          -  Life expectancy > or = 8 weeks

          -  Patients were enrolled at least 14 days after stereotactic biopsy and 28 days after
             surgical biopsy.

          -  CT or brain MRI was performed within 4 weeks before treatment to rule out haemorrhage.

          -  Included to health social security system

          -  Medical assessment previous to inclusion

          -  Informed consent form

        Exclusion Criteria:

          -  Previous treatment with Surgical resection, RT or chemotherapy to the tumor.

          -  Hemoglobin level < 9 g%

          -  Absolute neutrophil count < 1500

          -  Platelet count < 100.000

          -  ASAT or ALAT levels more than 3 times the upper limit of normal.

          -  Bilirubin levels more than 2 times the upper limit of normal

          -  Creatinin more than 1.5 times the upper limit of normal

          -  Untreated high blood pressure >150/100 mmHg

          -  Congestive cardiac failure

          -  Proteinuria > 1 gr/24h

          -  INR > 1.5 the upper limit of normal

          -  Recent symptomatic haemorrhage

          -  History of abnormal wound healing

          -  Gastrointestinal fistula

          -  Haemoptysis > grade 2 (NCI-CTC)

          -  Intracranial abscess

          -  Coagulation disorder

          -  Active infection requiring intravenous antibiotics

          -  Vascular disease (including myocardial infarction, unstable angina, cerebrovascular
             disease, peripheral arterial or aortic disease) in the previous 6 months

          -  Malignancy diagnosed in the previous 5 years (except basocellular skin cancer and in
             situ cervix cancer)

          -  Allergy to dacarbazine, Bevacizumab, Temozolomide or their excipients, recombinant
             human monoclonal antibodies, or ovarian cells of Chinese hamsters.
Clinical trial NCT01059825 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo to ertugliflozin, ertugliflozin 1 mg, ertugliflozin 5 mg, ertugliflozin 25 mg, sitagliptin 100 mg, placebo to sitagliptin, metformin
SMILES: CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with type 2 diabetes on stable doses of background medicines for
             management of the diabetes; aged 18-70 years; body mass index between 23-45 kg/m^2

        Exclusion Criteria:

          -  Participants with type 1 diabetes, heart attack or stroke in last 6-months,
             uncontrolled blood pressure, significant kidney disease
Clinical trial NCT00219908 (phase 2, status: terminated)
Conditions: relapsing-remitting multiple sclerosis
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: mitoxantrone
SMILES: OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  age : 18-45 years,

          -  Clinical disease satisfying the Poser criteria (Amdmt n°4)

          -  relapsing-remitting disease (Amdmt N°4)

          -  at least 2 exacerbations within the preceding 12 months, having left sequelae,

          -  MRI activity at inclusion expressed by at least one gadolinium-enhanced lesion
             (cranial MRI with 0.1mmol/kg gadolinium),

          -  a significant disability at inclusion: EDSS score between 2.5 and 5.5 (Amdt N° 4)

          -  written informed consent

        Exclusion Criteria:

          -  pregnancy and breast-feeding

          -  use of an insufficiency effective contraceptive method,

          -  general immunosuppressive therapy using cyclophosphamide, mitoxantrone,or total
             lymphoid irradiation

          -  treatment with azathioprine during the 3 months preceding the study

          -  clinical relapse or intensive corticosteroid treatment within the 30 days preceding
             inclusion,

          -  associated disease (psychiatric disorder, depressive statenot controlled by
             appropriate drug therapy, history of heart disease at inclusion examination